Try our mobile app
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
| ||
| (State of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
|
|
| |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant's telephone number, including area
code:
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share SRTS Nasdaq Stock Market, LLC
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SENSUS HEALTHCARE, INC.
FORM 8-K
CURRENT REPORT
| Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
On January 27, 2022, Michael J. Sardano was elected President of the Company, to serve until the next annual meeting of the Company’s Board of Directors, subject to his earlier resignation, removal, or death. Mr. Michael Sardano, age 33, will continue to serve as the Company’s General Counsel. Information concerning Mr. Michael Sardano, including his background and experience, family relationships, and compensation (including his employment agreement with the Company), is incorporated by reference to the sections entitled “Executive Officers,” “Certain Relationships and Related Party Transactions – Relationship of Certain Employees,” and “Executive Compensation” in the Company’s proxy statement for its 2021 annual meeting of shareholders.
In connection with the election of Michael Sardano, Joseph C. Sardano, Chairman, President, and Chief Executive Officer of Sensus Healthcare, Inc. (the “Company”), resigned as President, effective January 27, 2022. He will retain the positions of Chairman and Chief Executive Officer.
Effective January 28, 2022, Stephen Cohen, Executive Vice President, Strategic Initiatives and Dermatology, of the Company, resigned.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SENSUS HEALTHCARE, INC. | ||
| Date: January 31, 2022 | By: | /s/ Javier Rampolla |
| Javier Rampolla | ||
| Chief Financial Officer | ||
